Healthobesity treatmentsobesity drugsGlobal
Next Wave of Obesity Drugs: GLP-1s and Beyond
New obesity drugs and GLP-1s offer hope for weight loss.
Executive Summary
The next wave of obesity drugs is on the horizon, with GLP-1s and new shots and pills in development, offering potentially fewer side effects and more convenience. Eli Lilly and Novo Nordisk are currently dominating the market, but new entrants are emerging. With over 3 million prescriptions of Novo's Wegovy pill in just five months, the market is expanding rapidly. According to Ray Stevens, CEO of Structure Therapeutics, competition will ultimately benefit patients.
Key Takeaways
- ✓Competition in the obesity drug market will benefit patients
- ✓New GLP-1s in development may have fewer side effects
- ✓The obesity epidemic is a significant concern in India
- ✓The market for obesity drugs is expected to grow significantly
- ✓New treatments will emerge in the next few years
#Eli Lilly#Novo Nordisk#Pfizer#GLP-1s#obesity medications#weight loss#India health
